- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05271370
An Extension Protocol for Virologically Suppressed Subjects Who Successfully Completed PRO140_CD03 Study
This study is a Phase 2b/3 multi-center extension study designed to evaluate the long term antiviral activity, safety, and tolerability of the strategy of continuing PRO 140 350mg, 525mg, or 700mg SC monotherapy to maintain viral suppression after initial 48 weeks in virologically suppressed subjects.
Consenting subjects will continue weekly PRO 140 350mg, 525mg, or 700mg monotherapy during the Treatment Extension Phase with the one week overlap of existing retroviral regimen and PRO 140 350mg, 525mg, or 700 mg at the end of the treatment in subjects who do not experience virologic failure.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
California
-
San Francisco, California, United States, 94115
- Quest Clinical Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects who have completed 48 weeks of treatment in PRO140_CD03 study.
- Last known Plasma HIV-1 RNA < 50 copies/mL within PRO140_CD03 study.
- Both male and female patients and their partners of childbearing potential must agree to use 2 medically accepted methods of contraception (e.g., barrier contraceptives [male condom, female condom, or diaphragm with a spermicidal gel], hormonal contraceptives [implants, injectables, combination oral contraceptives, transdermal patches, or contraceptive rings], and intrauterine devices) during the course of the study (excluding women who are not of childbearing potential and men who have been sterilized). Females of childbearing potential must have a negative serum pregnancy test at Screening visit and negative urine pregnancy test prior to receiving the first dose of study drug.
- Willing and able to participate in all aspects of the study, including use of SC medication, completion of subjective evaluations, attendance at scheduled clinic visits, and compliance with all protocol requirements as evidenced by providing written informed consent.
Exclusion Criteria:
- Not currently enrolled in PRO140_CD03 study.
- Any active infection or malignancy requiring acute therapy (with the exception of local cutaneous Kaposi's sarcoma).
- Females who are pregnant, lactating, or breastfeeding, or who plan to become pregnant during the study.
- Subjects weighing < 35kg.
- History of anaphylaxis to any oral or parenteral drugs.
History of Bleeding Disorder or patients on anti-coagulant therapy (except aspirin).
Note: Subjects with well-controlled bleeding disorder while on stable anti-coagulant therapy dose with documented stable INRs can be enrolled as per discretion of the Investigator.
- Any other clinical condition that, in the Investigator's judgment, would potentially compromise study compliance or the ability to evaluate safety/efficacy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PRO 140 350 mg
PRO 140 350mg weekly SQ injection.
|
Pro140 SC injection 350 mg
|
Experimental: PRO 140 525 mg
PRO 140 525mg weekly SQ injection.
|
525 mg
|
Experimental: PRO 140 700 mg
PRO 140 700mg weekly SQ injection.
|
700 mg
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Long term clinical safety of PRO 140 350mg, 525, or 700 mg monotherapy regimen will be measured based on participants With Treatment-Related Adverse Events
Time Frame: 200 weeks
|
200 weeks
|
Proportion of participants experiencing virologic failure, defined as two consecutive HIV-1 RNA levels of ≥ 200 copies/mL for all subjects and within each treatment group will be measured
Time Frame: 200 weeks
|
200 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time to virologic failure, defined as two consecutive HIV-1 RNA levels of ≥ 200 copies/mL for all subjects and within each treatment group will be measured
Time Frame: 200 weeks
|
200 weeks
|
Proportion of participants achieving viral re-suppression (HIV-1 RNA < 50 copies/mL) after experiencing virologic failure for all subjects and within each treatment group will be measured
Time Frame: 200 weeks
|
200 weeks
|
Time to achieving viral re-suppression (HIV-1 RNA < 50 copies/mL) after experiencing virologic failure for all subjects and within each treatment group will be measured
Time Frame: 200 weeks
|
200 weeks
|
Proportion of virologic failure subjects achieving viral re-suppression (HIV-1 RNA < 50 copies/mL) with re-initiation of previous baseline antiretroviral regimen for all subjects and within each treatment group will be measured
Time Frame: 200 weeks
|
200 weeks
|
Mean change in CD4 cell count, at each visit within the Treatment Phase for all subjects will and within each treatment group will be measured
Time Frame: 200 weeks
|
200 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PRO 140_CD03 Extension
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV-1-infection
-
Sociedad Andaluza de Enfermedades InfecciosasConsejeria de Salud. Junta de Andalucia. SpainCompletedHIV Infection | HIV-1 InfectionSpain
-
Helios SaludViiV HealthcareUnknownHiv | HIV-1-infectionArgentina
-
Frontier Biotechnologies Inc.RecruitingHIV-1-infectionUnited States
-
University of ZurichActive, not recruitingHIV-1-infectionSwitzerland
-
MacroGenicsNational Institute of Allergy and Infectious Diseases (NIAID)CompletedHIV-1-infectionUnited States
-
Fundación FLS de Lucha Contra el Sida, las Enfermedades...Aelix TherapeuticsCompleted
-
University of North Carolina, Chapel HillNational Institute of Allergy and Infectious Diseases (NIAID)CompletedHIV-1 InfectionUnited States
-
Taipei Veterans General Hospital, TaiwanCompleted
-
Shanghai Public Health Clinical CenterUnknown
-
Fundación FLS de Lucha Contra el Sida, las Enfermedades...Completed
Clinical Trials on PRO 140 350
-
CytoDyn, Inc.Active, not recruiting
-
Bausch Health Americas, Inc.Completed
-
CytoDyn, Inc.Active, not recruiting
-
CytoDyn, Inc.Amarex Clinical ResearchCompletedHIV | Human Immunodeficiency VirusUnited States
-
CytoDyn, Inc.Amarex Clinical ResearchCompletedNonalcoholic Steatohepatitis (NASH)United States
-
CytoDyn, Inc.Amarex Clinical ResearchActive, not recruitingTriple Negative Breast NeoplasmsUnited States
-
Bexion Pharmaceuticals, Inc.CTI Clinical Trial and Consulting ServicesRecruitingDiffuse Intrinsic Pontine Glioma | Diffuse Midline Glioma, H3 K27M-MutantUnited States
-
The Baruch Padeh Medical Center, PoriyaUnknownOsteoarthritis of Acromioclavicular Joint